Historical resistance profile helps to predict salvage failure

Background This study compared the predictive value for treatment failure of extended resistance detected in the current genotype resistance test (GRT) versus those from GRT history in patients with multiple combination anti-retroviral therapy (cART) failures. Methods Patients who underwent three GRT between 1999 and 2007 were included. Extended resistance at genotypic sensitivity score (GSS) using the Rega 7.1 interpretation system compared with a non-standard definition (defined as class-wide resistance [CWR] on the basis of International AIDS Society–USA mutations) was assessed both for current and historical GRTs (a combination of mutations was detected in all three tests). The predictive role of extended resistance for treatment failure was evaluated with an adjusted Cox proportional hazard model. Results Overall, 177 patients were included. The historical GRT increased the number of patients with extended resistance to all three major drug classes by 25% in comparison with the current GRT. Using the GSS method, the absence of detection of any active drug in any drug class was predictive of failure with both the current and historical GRTs. Similarly, the number of active drugs in the cART regimen after the third resistance test, used as continuous variable, was also predictive of failure. Using both GSS approaches, current genotype had a higher effect than historical genotype on risk of treatment failure. Using the non-standard definition (CWR), historical resistance predicted failure better than current resistance. Conclusions Our results provide an epidemiological demonstration that analysis of a combined latest and historical GRT, which also considers archived mutations, might better identify of the more virologically impaired patients in order to assess the best salvage treatment.

[1]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Vincent Calvez,et al.  No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients , 2005, AIDS.

[3]  J. Ioannidis,et al.  Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis , 2004, AIDS.

[4]  H. Günthard,et al.  Drug Resistance Mutations during Structured Treatment Interruptions , 2002, Antiviral therapy.

[5]  Robert T. Schooley,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). , 1997, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.

[6]  P. Harrigan,et al.  Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.

[7]  D. Costagliola,et al.  Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Huldrych F Günthard,et al.  Update of the drug resistance mutations in HIV-1: Spring 2008. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[9]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[10]  Eoin Coakley,et al.  Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  F. Antunes,et al.  Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen , 2007, AIDS.

[12]  R. Haubrich,et al.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.

[13]  P. Narciso,et al.  Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome , 2005, Antiviral therapy.

[14]  R. Haubrich,et al.  Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2007, The Lancet.

[15]  J. Montaner,et al.  Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials , 2005, Journal of acquired immune deficiency syndromes.

[16]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[17]  P. Narciso,et al.  Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART. , 2008, AIDS research and human retroviruses.

[18]  N. Ghoraf.  Reliability formula & limit law of the failure time of “m-consecutive-k-out-of-n:F system” , 2008 .

[19]  F. Clavel,et al.  HIV Drug Resistance , 2000, The New England journal of medicine.

[20]  Julio S. G. Montaner,et al.  Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.

[21]  P. Harrigan,et al.  Clinical utility of testing human immunodeficiency virus for drug resistance. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Antinori Andrea,et al.  Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: a 6 year follow-up analysis of a large observational database , 2007, AIDS.

[23]  D. Costagliola,et al.  Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals , 2005, Antiviral therapy.

[24]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.